Trial record 5 of 9 for:
progeria
Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03895528 |
|
Expanded Access Status :
Available
First Posted : March 29, 2019
Last Update Posted : February 16, 2021
|
Sponsor:
Eiger BioPharmaceuticals
Information provided by (Responsible Party):
Eiger BioPharmaceuticals
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
| Tracking Information | |||||
|---|---|---|---|---|---|
| First Submitted Date | March 27, 2019 | ||||
| First Posted Date | March 29, 2019 | ||||
| Last Update Posted Date | February 16, 2021 | ||||
| Descriptive Information | |||||
| Brief Title | Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome or Progeroid Laminopathy | ||||
| Brief Summary | This treatment IND protocol will allow patients with HGPS and progeroid laminopathies access to lonafarnib, the only compound shown to have an effect on the HGPS disease process resulting in improved outcomes (Gordon et al, 2018). There are no approved treatments for HGPS and progeroid laminopathies. | ||||
| Detailed Description | Not Provided | ||||
| Study Type | Expanded Access | ||||
| Expanded Access Type | Treatment IND/Protocol | ||||
| Intervention | Drug: Lonafarnib
Farnesyl transferase inhibitor
Other Name: FTI
|
||||
| Publications * | Gordon LB, Shappell H, Massaro J, D'Agostino RB Sr, Brazier J, Campbell SE, Kleinman ME, Kieran MW. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. JAMA. 2018 Apr 24;319(16):1687-1695. doi: 10.1001/jama.2018.3264. | ||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
| Recruitment Information | |||||
| Expanded Access Status | Available | ||||
| Contacts |
|
||||
| Listed Location Countries | Not Provided | ||||
| Removed Location Countries | |||||
| Administrative Information | |||||
| NCT Number | NCT03895528 | ||||
| Responsible Party | Eiger BioPharmaceuticals | ||||
| Study Sponsor | Eiger BioPharmaceuticals | ||||
| Collaborators | Not Provided | ||||
| Investigators | Not Provided | ||||
| PRS Account | Eiger BioPharmaceuticals | ||||
| Verification Date | February 2021 | ||||